Area: Strategy
CEOs Risk Alienating Customers with High-Profile Activism
Taking a stand on controversial issues can hurt sales, but the effect is brief
CEO Succession: Execs Running a Subsidiary Offer a Balance Between Insider and Outsider
In an analysis of transitions from 1993 to 2017, they wrung more from operations facing tumult
Assessing Climate Disclosure as U.S. Drops Scope 3 Requirement
What emerges is a fragmented view of corporate contribution to global warming
Academic Medical Centers Resilient After Cuts
Following Medicare reimbursement rate changes, research actually increased
A Guide for Companies That Want to Restore Credibility to Climate Disclosures
Identify and come clean about the layered uncertainties, both in measurement and in outcomes
A Case Against Experience as a Central Driver of Innovation
Are older inventors weighed down by obsolete knowledge? Young inventors don’t carry that burden
A Broader Measure of Value Creation at Corporations
A tool in the debate over shareholder primacy and wealth disparities
$52.6 Billion: Extra Cost to Consumers of Add-On Drug Patents
The figure is a subset, not covering huge expense of extended patents on high-priced biologics like Humira